Skip to main content
. 2021 Mar 5;14:1756286421999631. doi: 10.1177/1756286421999631

Figure 4.

Figure 4.

Patients who received therapy with CYP, RTX, or BTZ within 24 months after diagnosis had a significantly higher therapeutic response rate after first therapy than those who were treated later (79.2% versus 50.0%, χ2-test, p = 0.034).

BTZ, bortezomib; CYP, cyclophosphamide; RTX, rituximab.